RxDoctor Payments Data

Michelle Hicks, NP

Adult Health · Boise, IDNPI 1508973991

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,675 of the $39,895 with a category attached, or 69.4%. AbbVie accounts for 99.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $16,139 and has fallen 88.9% since, to $1,790 in 2025. Among adult health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,895in general payments, 2019–2025

Across 112 payments — averaging $356.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$40K
  • Johnson & Johnson$78
  • Pfizer$64
  • Novartis$64
  • Regeneron Healthcare Solutions, Inc.$61
  • Boehringer Ingelheim$50
  • plus $65 from 2 others

What the payments were for

  • Speaking & faculty fees$27,67569%
  • Travel & lodging$9,80525%
  • Food & beverage$2,4156%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,895 in reported general payments places this provider in the 95th percentile of 38 adult health providers in Idaho.

See all adult health providers in Idaho

Medicare billing

Part B allowed, 2024
$20,935
Medicare patients
135
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib93$559,185
IlarisCanakinumab/Pf13$435,734
Xeljanz XrTofacitinib Citrate59$317,703
Cimzia (2 Pack)Certolizumab Pegol40$299,569
Enbrel SureclickEtanercept17$122,071
BenlystaBelimumab25$118,919
OrenciaAbatacept18$97,548
EnbrelEtanercept13$96,610
Humira(Cf) PenAdalimumab11$83,765
SimponiGolimumab13$71,502
Actemra ActpenTocilizumab18$68,641
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5019$57,569
TymlosAbaloparatide20$50,703
ActemraTocilizumab12$28,121
Hydroxychloroquine Sulfate249$10,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$39,512$559,18593 claims
NovartisIlaris$64$435,73413 claims
UCB, Inc.Cimzia (2 Pack)$28$299,56940 claims
Johnson & JohnsonSimponi$78$71,50213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 adult health providers in Idaho.

Other adult health in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →